Navigation Links
NeurogesX Responds to EMEA's Day 120 Questions
Date:9/24/2008

Regulatory Plans on Track

SAN MATEO, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that it has responded on schedule to the European Medicines Agency's (EMEA) Day 120 questions to support the Marketing Authorization Application (MAA) for NGX-4010 in peripheral neuropathic pain.

NeurogesX' MAA for NGX-4010 in peripheral neuropathic pain was accepted for review by the EMEA in September 2007. The Day 120 questions and related responses are part of the agency's ongoing review process of the marketing application.

Anthony DiTonno, President and CEO, commented, "With the submission of our responses to the EMEA's Day 120 questions, we are pleased to reiterate that our regulatory timelines for NGX-4010 remain on track with respect to the MAA review in Europe and our plans to submit a new drug application to the FDA by year end."

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... A report on the California biomedical industry published ... success stories from Larta Institute, a consulting firm that ... to market. According to CHI,s 2011 ... growing force in the past few years in the ...
... BOSTON, Feb. 11, 2011 Tufts University today announced ... Partnerships Web site/HUB:   www.tuftspharmapartners.org .   ... designed to create and manage a diverse portfolio of ... Institute was developed and is managed by Tufts University ...
... LOS ANGELES, Feb. 11, 2011 Genesis Biopharma, ... a biotechnology company developing targeted cancer therapies, today announced ... Chief Executive Officer.  Mr. Cataldo succeeds Robert Brooke, who ...  In addition, the Company named Michael Handelman as Chief ...
Cached Biology Technology:Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report 2Tufts Launches Institute for Biopharmaceutical Partnerships 2Tufts Launches Institute for Biopharmaceutical Partnerships 3Tufts Launches Institute for Biopharmaceutical Partnerships 4Genesis Biopharma Announces Management and Board Changes 2Genesis Biopharma Announces Management and Board Changes 3
(Date:7/11/2014)... Conservation Society shows that no-take zones in Belize ... as lobster, conch, and fish recover from overfishing, ... , The reporttitled "Review of the Benefits of ... from no-take areas around the world. The report ... expert in marine protected areas and fisheries management. ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2New simple setup for X-ray phase contrast 2
... that tamps down stem cell activity ironically, perhaps, encourages ... researchers report. Understanding how these new brain cells "decide" ... is of special interest because changes in their activity ... illness and aging. "We,ve identified a critical ...
... United States has resulted in the discovery of a ... diseases particularly eosinophil-associated disorders. The researchers from ... have discovered how this pathway kills eosinophils before they ... the blood, but when the body produces too many ...
... researchers have found that zinc can ,starve, one of ... of an essential metal. The finding, by infectious ... University of Queensland, opens the way for further work ... Streptococcus pneumoniae . Streptococcus pneumoniae is ...
Cached Biology News:SIGNAL found to enhance survival of new brain cells 2Discovery may lead to new treatments for allergic diseases 2How zinc starves lethal bacteria to stop infection 2
...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
Biology Products: